Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models
Endocrine Abstracts · 07.05.2022
DOI: 10.1530/endoabs.81.p608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 07.05.2022. Verfasst von Conceicao Ismael da und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
Zitieren
APA
da, C. I., Nikolaou, N., Gathercole, L., Harris, S., Dempster, N., Moolla, A., Hodson, L., & Tomlinson, J. (2022). Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models. Endocrine Abstracts. https://doi.org/10.1530/endoabs.81.p608
Vancouver
da CI, Nikolaou N, Gathercole L, Harris S, Dempster N, Moolla A, et al. Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models. Endocrine Abstracts. 2022. doi:10.1530/endoabs.81.p608
BibTeX
@article{da2022,
author = {da, Conceicao Ismael and Nikolaou, Nikolaos and Gathercole, Laura and Harris, Shelley and Dempster, Niall and Moolla, Ahmad and Hodson, Leanne and Tomlinson, Jeremy},
title = {Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models},
journal = {Endocrine Abstracts},
year = {2022},
doi = {10.1530/endoabs.81.p608}
}
EUVIMED